MGX实时信号 | 通过Getagraph.com最大化利润

出售 136650 min ago

@ $12.23

发出时间: 15 Feb 2024 @ 02:22

回报率: -42.76%

上一信号: Feb 14 - 03:08

上一信号: 购买

回报率: 5.43 %

Live Chart Being Loaded With Signals

Commentary (18 May 2024 @ 04:00):

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States...

Stats
今日成交量	52 467.00
平均成交量	132 130
市值	262.25M
下一个收益日期	( $0 ) 2024-06-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0140 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-08	Novo Holdings A/s	Sell	147 415	SERIES B PREFERRED STOCK
2024-02-08	Novo Holdings A/s	Sell	691 760	SERIES B-1 PREFERRED STOCK
2024-02-08	Noonberg Sarah B.	Sell	0	Common Stock
2024-02-08	Borges Luis	Buy	0

INSIDER POWER
-100.00
Last 3 transactions
Buy: 0 \| Sell: 839 175

音量相关性

長: 0.01 (neutral)

短: 0.11 (neutral)

Signal:(52.84) Neutral

Metagenomi, Inc. Common 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Metagenomi, Inc. Common 相关性 - 货币/商品

0.42
( neutral )

-0.28
( neutral )

0.00
( neutral )

0.18
( neutral )

0.30
( neutral )

Financial Reports:

No articles found.

Metagenomi, Inc. Common Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Metagenomi, Inc. Common

Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.